A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
ConditionRheumatoid Arthritis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Eligibility criteria
Qualifiers
Inclusion
Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
Have a positive ACPA at screening.
Disqualifiers
None
Trial design
Treatments tested in this trial
- AZD1163
- Placebo
Treatment groups
320 Participants
are divided into 4 treatment groupsLocations
144Argentina
Research SiteC1128AAF, Caba Argentina
Research SiteC1015ABO, Ciudad de Buenos Aires Argentina
Research SiteC1428DUQ, Ciudad de Buenos Aires Argentina
Research SiteX5000EDC, Córdoba Argentina
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov